Roche

News

Roche's Tecentriq extends lead over Keytruda in adjuvant NSC...

While Merck & Co's Keytruda is the undisputed leader of the non-small cell lung cancer (NSCLC) category, there's one category where it lags behind Roche's Tecentriq – treatment of early

News

EU first to clear Roche's lymphoma bispecific mosunetuzumab

Roche has secured its first regulatory approval for mosunetuzumab, a first-in-class CD20xCD3 bispecific antibody, as a treatment for patients with follicular lymphoma (FL) in the EU.

News

Roche puts pressure on SMA rivals with new FDA approval

Roche and PTC Therapeutics' Evrysdi for spinal muscular atrophy (SMA) has been approved by the FDA for younger children with the rare disease, extending its use to include infants less than

News

Roche trumpets new glofitamab data in lymphoma at ASCO

Roche will present the new data at next week's ASCO congress showing that its bispecific antibody glofitamab can achieve high and durable responses in patients with aggressive lymphoma.

News

NICE finds solution to making Keytruda available for TNBC

Around 100 patients in England and Wales with triple negative breast cancer (TNBC) that has spread to other parts of the body could soon access treatment with Merck & Co/MSD's Keytruda,

News

GSK, iTeos take stock after Roche's TIGIT setback

iTeos Therapeutics has said it is evaluating with partner GlaxoSmithKline whether to conduct additional clinical trials of TIGIT drug EOS-448 following the failure of a key trial for Roche'

Roche's Tecentriq extends lead over Keytruda in adjuvant NSC...

EU first to clear Roche's lymphoma bispecific mosunetuzumab

Roche puts pressure on SMA rivals with new FDA approval

Roche trumpets new glofitamab data in lymphoma at ASCO

NICE finds solution to making Keytruda available for TNBC

GSK, iTeos take stock after Roche's TIGIT setback

ADARx, Trex, and Retension take aim at IPOs

Discover a new era of healthcare panel engagement: Grounded ...

Roche

Editor's Picks